Efficacy and Safety Study of Pembrolizumab (MK-3475) in Combination With Daratumumab in Participants With Relapsed Refractory Multiple Myeloma (MK-3475-668/KEYNOTE-668)

NCT03221634 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL: Pembrolizumab
BIOLOGICAL: Daratumumab

Sponsor

Merck Sharp & Dohme LLC